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Abstract
Pasireotide, a multireceptor-targeted somatostatin analog with highest affinity for 
somatostatin receptor subtype (SST) 5, has demonstrated superior efficacy over the 
SST2-preferential somatostatin analogs octreotide and lanreotide. The safety profile is 
similar to those of octreotide and lanreotide, except for a higher frequency and degree 
of hyperglycemia. This analysis investigated baseline characteristics and occurrence and 
management of hyperglycemia during pasireotide treatment in patients with acromegaly 
treated in two prospective clinical studies, SOM230C2305 (C2305) and SOM230C2402 
(C2402; PAOLA). One hundred and seventy-eight patients naïve to medical therapy at 
baseline (C2305) and 125 uncontrolled on first-generation somatostatin analogs at 
baseline (C2402) received long-acting pasireotide in these studies. Of patients treated with 
pasireotide in studies C2305 and C2402, respectively, 75.3 (134/178) and 65.6% (82/125) 
developed hyperglycemia or experienced worsening of existing hyperglycemia. Occurrence 
of hyperglycemia during pasireotide treatment was less frequent in patients with lower 
age (<40 years, C2402; <30 years, C2305), normal glucose tolerance, and no history of 
hypertension or dyslipidemia at baseline. Thirteen (4%) patients discontinued pasireotide 
because of hyperglycemia-related adverse events. Metformin alone or in combination 
with other oral antidiabetic medications controlled elevations in glucose levels in most 
pasireotide-treated patients; 78% of C2305 patients and 73 (pasireotide 40 mg) and 60% 
(pasireotide 60 mg) of C2402 patients achieved the ADA/EASD goal of HbA1c <7% (<53 
mmol/mol) at the end of the core phase. Not all patients develop hyperglycemia, and it is 
reversible upon pasireotide withdrawal. Close monitoring, patient education and prompt 
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Acromegaly is a chronic endocrine disorder typically 
caused by a benign tumor of the pituitary gland (1), which 
hypersecretes growth hormone (GH) with subsequent 
secretion of insulin-like growth factor I (IGF-I). Long-term 
excess of GH and IGF-I results in multiple comorbidities 
(2, 3), including hypertension and metabolic disturbances 
(4, 5), which contribute to increased mortality (6). 
Restoration of GH and IGF-I levels to normal levels is a 
key treatment goal in acromegaly and can reduce disease-
associated morbidity and mortality (7, 8). Long-acting 
octreotide or lanreotide Autogel is the current standard of 
medical care for acromegaly (7). However, many patients 
do not achieve biochemical control with these agents (9).
Long-acting pasireotide, a multireceptor-targeted 
somatostatin analog (SSA), has been evaluated in the 
Phase III SOM230C2305 (C2305) (10) and SOM230C2402 
(C2402; PAOLA) (11) studies. Patients enrolled in study 
C2305 had active acromegaly and had not received 
medical therapy at study entry (10), while patients in 
study C2402 were uncontrolled on first-generation SSAs 
prior to start of study (11). The primary endpoint for both 
studies was the proportion of patients with biochemical 
control (defined as GH <2.5 µg/L and normal IGF-I) at 
months 12 and 6, respectively. In study C2305, long-acting 
pasireotide treatment was associated with biochemical 
control in a significantly greater proportion of patients 
than long-acting octreotide (31.3% vs 19.2%; P = 0.007) 
at month 12; this difference was driven by greater 
reductions in IGF-I with pasireotide than with octreotide 
(10). The pronounced effect of pasireotide on IGF-I levels 
may be mediated not only by the inhibition of pituitary 
GH secretion but also through non-pituitary actions 
of pasireotide, including insulin suppression (12, 13). 
Similarly, in the C2402 study, significantly more patients 
on long-acting pasireotide 40 (15.4%; P = 0.0006) and 60 
mg (20.0%; P < 0.0001) had biochemical control at month 
6 than those who continued treatment with long-acting 
octreotide 30 mg or lanreotide Autogel 120 mg (0.0%). In 
both studies, the safety profile of long-acting pasireotide 
was generally similar to that of octreotide and lanreotide, 
except for the frequency and degree of hyperglycemia.
Pasireotide binds with high affinity to four of the five 
somatostatin receptor subtypes (SST): SST1, SST2, SST3 and 
SST5 (14), with highest affinity for SST5 (39-fold higher 
affinity than octreotide) (15). The efficacy of pasireotide 
in controlling GH and IGF-I levels is attributed to its 
activation of SST2 and SST5, which are most prevalent 
on somatotroph adenomas (16). Both of these receptors 
also play important roles in blood glucose regulation. 
Insulin secretion is mediated by both SST2 and SST5 (17), 
whereas glucagon secretion is mediated mainly by SST2 
(18). As pasireotide has a higher affinity for SST5 than 
for SST2, insulin is suppressed to a greater degree than 
glucagon, which results in increased glucose levels (19). 
Indeed, pasireotide has been shown to reduce secretion 
of insulin, glucagon, glucagon-like peptide 1 (GLP-1) 
and glucose-dependent insulinotropic peptide in healthy 
volunteers (20). Thus, the reported effects of pasireotide 
on glucose homeostasis (10, 11) are likely the result 
of a decrease in both incretin response and insulin 
secretion (20).
Although the majority of patients receiving pasireotide 
will experience elevated glucose levels (hyperglycemia-
related adverse events (AEs) were experienced by 57 
and 64% of patients in C2305 (10) and C2402 (11), 
respectively), not all patients will develop hyperglycemia, 
and the magnitude of increase differs significantly between 
patients. The current work sought to investigate potential 
contributing factors to these differences in patients 
who participated in the C2305 and C2402 studies. Use 
of antidiabetic medications to manage hyperglycemia 
during pasireotide treatment was also assessed.
Methods
Study population and design
In study C2305, medical-therapy-naïve patients with active 
acromegaly (mean GH >5 µg/L or GH nadir ≥1 µg/L after 
an oral glucose tolerance test and IGF-I above the upper 
limit of normal (ULN)) were enrolled. Patients could have 
had previous pituitary surgery but no medical treatment, 
or were de novo with a visible pituitary adenoma on MRI 
(10). Patients were randomized in a double-blind manner 
to long-acting pasireotide 40 mg/28 days (n = 176) or long-
acting octreotide 20 mg/28 days (n = 182). Uptitration to 
long-acting pasireotide 60 mg or long-acting octreotide 
30 mg was permitted, but not mandatory, at months 3 
and 7 if biochemical control (defined as GH <2.5 µg/L 
and normal IGF-I) was not achieved. The study consisted 
of two phases: a 12-month core phase and an optional 
extension phase in which patients achieving biochemical 
control or deriving benefit from treatment (investigator 
discretion) could continue their randomized treatment, 
otherwise they could cross over to the other treatment. 
Further study details have been published elsewhere (10). 
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In study C2402, patients with uncontrolled 
acromegaly (mean GH ≥2.5 μg/L and IGF I >1.3 × ULN) 
following ≥6 months of long-acting octreotide 30 mg or 
lanreotide Autogel 120 mg monotherapy were randomized 
to long-acting pasireotide 40 mg (n = 65), 60 mg (n = 65), 
or continued treatment with long-acting octreotide 30 
mg or lanreotide Autogel 120 mg (active control; n = 68). 
Further study details have been published elsewhere (11).
Patients with inadequately controlled diabetes, 
as evidenced by glycated hemoglobin (HbA1c) >8% 
(>63.9 mmol/mol) despite treatment with antidiabetic 
medication(s), were not eligible to participate in studies 
C2305 and C2402. Patients with a known history or 
a new diagnosis of impaired fasting plasma glucose or 
diabetes mellitus were allowed to participate in each 
study; however, the study protocols stipulated that their 
blood glucose levels and antidiabetic treatment were to 
be closely monitored throughout these studies, with the 
latter adjusted as necessary.
Definitions of C2305 and C2402 subpopulations based 
on diabetic status are provided in the Supplementary 
material (see section on supplementary materials given at 
the end of this article). The number of patients deemed 
to have diabetes, pre-diabetes or normal glucose tolerance 
at baseline in this analysis of the C2402 study is different 
from the number classified as such in the primary 
publication of the study because of subtle differences in 
definitions between the two publications; in particular, 
the definitions of diabetes, pre-diabetes and normal 
glucose tolerance were updated for the current analysis to 
align them with guidelines set by the American Diabetes 
Association (ADA) for the classification of diabetes 
(Supplementary Table).
Studies C2305 and C2402 were conducted in accordance 
with the Declaration of Helsinki, and an independent 
ethics committee or institutional review board for each 
study site approved the relevant study protocol (see 
Supplementary material for full details). Consent was 
obtained from each patient or subject after full explanation 
of the purpose and nature of all procedures used.
Hyperglycemia-related adverse events
Investigators were recommended to follow established 
guidelines by expert international diabetes organizations 
such as the ADA and the European Association for 
the Study of Diabetes (EASD). Hyperglycemia-related 
AEs were reported by the study investigators using 
various terms and included, but were not limited to, 
hyperglycemia (based on fasting glucose), diabetes 
mellitus, increased blood glucose, and type 2 diabetes 
mellitus. All AEs related to hyperglycemia were grouped 
together as hyperglycemia-related AEs. AEs were reported 
according to Common Terminology Criteria for Adverse 
Events (CTCAE) version 4.0.
Definitions of antidiabetic medication categories
The efficacy of antidiabetic therapeutic regimens with 
regard to hyperglycemia during pasireotide treatment 
was assessed for both studies. Owing to the wide variety 
of antidiabetic medications that were used during the 
study periods, for the current analysis, three antidiabetic 
treatment groups were defined:
• ‘Metformin alone’ included patients who took at 
least one dose of metformin alone with no other oral 
antidiabetic (OAD) or insulin throughout the core phase
• ‘Metformin ± OAD’ included patients who received 
either metformin along with an OAD or any OAD 
other than metformin alone at any point during the 
core phase
• ‘Insulin ± OAD’ included patients who took insulin 
at any point during the core phase of the study with 
or without an OAD (which could have included 
metformin)
OADs included dipeptidyl peptidase 4 inhibitors, 
sulfonylureas, meglitinides, thiazolidinediones and 
alpha-glucosidase inhibitors. Only two patients, both 
in the C2402 study, received a GLP-1 receptor agonist 
(liraglutide); these two patients were not included in these 
analyses. 
Assessments and statistical analysis
All blood samples for assessment of fasting plasma glucose 
(FPG) and HbA1c were taken after an overnight fast and 
before administration of long-acting pasireotide. 
This study reports the baseline characteristics and 
occurrence and management of hyperglycemia in patients 
with acromegaly who were either naïve to medical therapy 
(C2305) or uncontrolled on first-generation SSAs (C2402) at 
baseline and were treated with pasireotide during the core 
phase of these studies. The occurrence and management 
of hyperglycemia in patients who crossed over from 
pasireotide to octreotide and vice versa in the extension 
phase of the C2305 study are also reported here. Descriptive 
statistics are presented for the current work. Further details 
on statistical analyses have been published elsewhere (10, 
11). Univariate logistic regression analysis was performed 
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on the safety analysis set (i.e. all patients who received 
at least one dose of study medication with a valid post-
baseline safety assessment) to explore factors that might 
impact on hyperglycemia. P values provided are nominal. 
No multiplicity adjustments were performed; therefore, 
statistical interpretation should be made with caution.
Results
Baseline characteristics of patients who did not 
experience hyperglycemia during treatment 
with pasireotide
Overall, 75.3% (134/178) of pasireotide-treated patients 
in study C2305, and 65.6% (82/125) in study C2402, 
experienced hyperglycemia-related AEs during the core 
phases of both trials (Table 1). Younger patients, and 
those without diabetes or a history of hypertension or 
dyslipidemia at baseline, constituted most of the patients 
not experiencing hyperglycemia during the studies.
Age
Mean ages were similar across the two studies. Patients <30 
years of age in study C2305, and <40 years of age in study 
C2402, were less likely to experience hyperglycemia with 
pasireotide than patients in older age categories (Table 1). 
However, within these age categories, the number of 
patients with diabetes at baseline varied: 7.5% (4/53) 
in study C2305 aged <30 years, and 37.8 (17/45) and 




40 mg 40 mg 60 mg
No (n = 44) Yes (n = 134) Noa (n = 25) Yesa (n = 38) Noa (n = 18) Yesa (n = 44)
Mean age, years (s.d.) 38.6 (11.5) 47.1 (11.9) 40.0 (14.1) 44.1 (14.0) 36.7 (9.4) 49.4 (14.5)
Age group, n (%)
 18–<30 years 12 (27.3) 8 (6.0) 6 (24.0) 7 (18.4) 6 (33.3) 4 (9.1)
 30–<40 years 12 (27.3) 34 (25.4) 8 (32.0) 6 (15.8) 6 (33.3) 5 (11.4)
 40–<50 years 10 (22.7) 30 (22.4) 5 (20.0) 12 (31.6) 4 (22.2) 17 (38.6)
 50–<60 years 9 (20.5) 45 (33.6) 4 (16.0) 10 (26.3) 2 (11.1) 7 (15.9)
 ≥60 years 1 (2.3) 17 (12.7) 2 (8.0) 3 (7.9) 0 11 (25.0)
Mean BMI, kg/m2 (s.d.) 28.1 (4.9) 28.9 (4.5) 27.8 (4.2) 30.1 (5.4) 27.6 (4.7) 31.0 (6.6)
Baseline diabetic status, n (%)
 NGT 27 (61.4) 30 (22.4) 6 (24.0) 1 (2.6) 8 (44.4) 4 (9.1) 
 Pre-diabetic 10 (22.7) 58 (43.3) 9 (36.0) 2 (5.3) 6 (33.3) 7 (15.9)
 Diabetic 7 (15.9) 46 (34.3) 10 (40.0) 35 (92.1) 4 (22.2) 33 (75.0)
Baseline FPG, n (%)
 <100 mg/dL (<5.6 mmol/L) 34 (77.3) 85 (63.4) 12 (48.0) 13 (34.2) 11 (61.1) 13 (29.5)
 100–<126 mg/dL (5.6–<7.0 mmol/L) 8 (18.2) 43 (32.1) 11 (44.0) 20 (52.6) 6 (33.3) 22 (50.0)
 ≥126 mg/dL (≥7.0 mmol/L) 1 (2.3) 6 (4.5) 2 (8.0) 5 (13.2) 1 (5.6) 9 (20.5)
 Missing data 1 (2.3) 0 0 0 0 0
Baseline HbA1c, n (%)
 <5.7% (<37.7 mmol/mol) 30 (68.2) 44 (32.8) 16 (64.0) 7 (18.4) 11 (61.1) 11 (25.0)
 5.7–<6.5% (37.7–<47.5 mmol/mol) 12 (27.3) 75 (56.0) 8 (32.0) 21 (55.3) 7 (38.9) 19 (43.2)
 6.5–<8.0% (47.5–<63.9 mmol/mol) 2 (4.5) 15 (11.2) 1 (4.0) 9 (23.7) 0 13 (29.5)
 Missing data 0 0 0 1 (2.6) 0 1 (2.3)
Baseline mean GH, µg/L (s.d.) 16.2 (20.7) 23.5 (34.8) 25.6 (53.5) 12.5 (16.6) 10.3 (10.0) 13.4 (25.6)
Baseline mean IGF-I, × ULN (s.d.) 2.4 (1.1) 3.2 (1.3) 2.3 (0.8) 2.6 (1.1) 2.2 (0.8) 3.0 (1.2)
Mean time since diagnosis, months (s.d.) 15.1 (23.8) 21.7 (50.6) 49.9 (46.2) 76.9 (68.7) 61.2 (42.5) 80.1 (73.1)
History of hypertension
 No 36 (81.8) 73 (54.5) 21 (84.0) 26 (68.4) 16 (88.9) 21 (47.7)
 Yes 8 (18.2) 61 (45.5) 4 (16.0) 12 (31.6) 2 (11.1) 23 (52.3)
History of dyslipidemia
 No 35 (79.5) 97 (72.4) 22 (88.0) 24 (63.2) 17 (94.4) 24 (54.5)
 Yes 9 (20.5) 37 (27.6) 3 (12.0) 14 (36.8) 1 (5.6) 20 (45.5)
aThis analysis of the C2402 study explored the effect of pasireotide on FPG and HbA1c levels according to whether patients developed hyperglycemia at 
any time after initiation of pasireotide, whereas previous analyses of the study reported on this only for patients who had an evaluable assessment at the 
end of the core study (28).
FPG, fasting plasma glucose; GH, growth hormone; HbA1c, glycated hemoglobin; IGF-I, insulin-like growth factor I; NGT, normal glucose tolerance; ULN, 
upper limit of normal.
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18.9% (7/37) in the pasireotide 40 and 60 mg treatment 
groups, respectively, in study C2402 aged <40 years. Of 
the diabetic patients at baseline in these younger age 
categories, 75.0% (3/4) in study C2305, and 70.6 (12/17) 
and 85.7% (6/7) in the pasireotide 40 and 60 mg treatment 
groups in study C2402, developed hyperglycemia while 
receiving pasireotide. Of the diabetic patients at baseline 
in the older age categories in studies C2305 (≥30 years) 
and C2402 (≥40 years), 87.8% (43/49) in study C2305, 
and 82.1 (23/28) and 90.0% (27/30) in the pasireotide 40 
and 60 mg treatment arms in study C2402, developed 
hyperglycemia during pasireotide treatment.
Diabetic status
In studies C2305 and C2402, 68.0 (121/178) and 84.8% 
(106/125) of patients, respectively, were diabetic or pre-
diabetic at baseline (Table 1). For patients with normal 
glucose tolerance (NGT) at baseline, 52.6% (30/57) of 
patients in study C2305, and 14.3 (1/7; 40 mg dose) and 
33.3% (4/12; 60 mg dose) of patients in study C2402, 
experienced hyperglycemia while receiving pasireotide. 
The percentages of patients who were diabetic at baseline 
and who did not experience post-baseline hyperglycemia 
with pasireotide were 13.2% (7/53) for C2305 patients 
and 22.2 (10/45; 40 mg dose) and 10.8% (4/37; 60 mg 
dose) for C2402 patients.
Hypertension
In patients without a history of hypertension who 
received pasireotide, 67.0% (73/109) of C2305 patients, 
and 55.3 (26/47; 40 mg dose) and 56.8% (21/37; 60 
mg dose) of C2402 patients, developed hyperglycemia 
(Table 1). Corresponding percentages for patients with a 
history of hypertension were 88.4 (61/69), 75.0 (12/16; 40 
mg dose) and 92.0% (23/25; 60 mg dose) for patients in 
studies C2305 and C2402, respectively.
Dyslipidemia
In studies C2305 and C2402, respectively, 73.5 (97/132), 
52.2 (24/46; 40 mg dose) and 58.5% (24/41; 60 mg dose) 
of patients without a history of dyslipidemia developed 
hyperglycemia with pasireotide treatment (Table 1). 
Corresponding percentages for patients with a history of 
dyslipidemia were 80.4 (37/46), 82.4 (14/17; 40 mg dose) 
and 95.2% (20/21; 60 mg dose). 
Risk factors for worsening glucose control
In both studies, diabetes mellitus and elevated HbA1c 
at baseline were predictive risk factors for worsening 
of glucose control during treatment with pasireotide 
(Table  2). Additional risk factors identified were age, a 
history of hypertension in patients from study C2305, and 
a history of dyslipidemia and BMI ≥30 kg/m2 in patients 
from study C2402 (Table 2).
Change in glycemic parameters by baseline 
diabetic status
In both study populations, those with diabetes at baseline 
receiving pasireotide had the greatest magnitude of 
increase in HbA1c and FPG (Fig. 1) compared with pre-
diabetic patients and those with NGT at baseline. Peak 
plasma glucose values following pasireotide therapy were 
observed at month 1 (C2402) and month 3 (C2305).
Glycemic control
The HbA1c values of individual patients were evaluated 
at month 12 (C2305) and month 6 (C2402), or at the 
last available time point for patients who discontinued 
treatment early. At the end of the core phases of both 
studies, 78.1% of C2305 patients and 73.0 (pasireotide 40 
mg) and 59.7% (pasireotide 60 mg) of C2402 patients had 
HbA1c values that met the ADA/EASD goal of <7% (<53.0 
mmol/mol). In study C2305, 54.7% of patients who were 
diabetic at baseline had a last HbA1c value of <7% (<53.0 
mmol/mol) vs 84.9% of diabetic patients at baseline, 
while 62.2 (pasireotide 40 mg) and 37.8% (pasireotide 60 
mg) of diabetic patients in study C2402 met the same goal 
(vs 84.4 and 73.0% of diabetic patients, respectively, at 
baseline).
The proportion of patients who achieved biochemical 
control of acromegaly (defined as GH <2.5 µg/L and 
normal IGF-I) was similar for patients who did and did 
not experience hyperglycemia on pasireotide: 31.6% vs 
30.2% (C2305), 15.8% vs 14.8% (C2402, pasireotide 40 
mg) and 18.2% vs 23.8% (C2402, pasireotide 60 mg) 
achieved biochemical control.
Safety profile
In both study populations, few or no patients with pre-
diabetes or NGT at baseline experienced grade 3 or 4 
hyperglycemia-related AEs during the core phases of both 
studies (Table 3). Grade 3–4 hyperglycemia-related AEs 
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were, however, more frequent in patients with diabetes 
at baseline.
Overall, only a small number of patients discontinued 
pasireotide because of hyperglycemia-related AEs (as 
judged by the investigator). In the core phases of studies 
C2305 and C2402 (pasireotide 40 and 60 mg), respectively, 
these AEs were: diabetes mellitus, n = 3 (1.7%), n = 1 
(1.6%), n = 1 (1.6%) and hyperglycemia, n = 2 (1.1%), 
n = 1 (1.6%), n = 3 (4.8%). Additionally, in study C2305, 
one patient (0.6%) discontinued pasireotide because of 
increased HbA1c, and one patient (0.6%) because of type 2 
diabetes mellitus.
Management of hyperglycemia
Patients in both trials who were not receiving 
antidiabetic therapy at study entry but who had 
antidiabetic medication initiated during the study were 
categorized into three analysis groups (metformin alone, 
metformin ± OAD, and insulin ± OAD) for exploratory 
assessment of FPG and HbA1c levels at study baseline 
and over time by antidiabetic treatment group. In study 
C2305, baseline median FPG and HbA1c values were similar 
in all three groups (Fig. 2A and B); following initiation 
of pasireotide, the greatest difference in median FPG 
and HbA1c values between antidiabetic treatment groups 
occurred at month 3. In study C2402, median FPG levels 
were largely stabilized after 3 months with metformin-
based antidiabetic medications (Fig. 2C and D). HbA1c 
values increased from baseline to month 3 for both 
doses of pasireotide regardless of antidiabetic treatment 
group; however, only one patient had evaluable data 
at month 6.
Reversibility of hyperglycemia
The reversibility of elevations in glucose levels in patients 
receiving long-acting pasireotide is supported by a rapid 
decrease in glucose levels in patients who crossed over 
from long-acting pasireotide to long-acting octreotide in 
Table 2 Logistic regression analysis of possible risk factors for developing hyperglycemia.
Risk factor
C2305 C2402
Odds ratio (95% CI) P value Odds ratio (95% CI) P value
Baseline age, years
 Per unit increase 1.04 (1.02, 1.05) <0.0005 1.02 (1.00, 1.04) 0.113
 ≥40 vs 40 1.76 (1.12, 2.76) 0.015 2.25 (1.21, 4.20) 0.01
BMI, kg/m2
 25–<30 vs <25 1.13 (0.63, 2.04) 0.673 1.31 (0.58, 2.99) 0.516
 ≥30 vs <25 0.90 (0.49, 1.66) 0.735 2.65 (1.14, 6.16) 0.023
Years with disease
 Per unit increase 1.02 (0.96, 1.09) 0.534 1.02 (0.97, 1.08) 0.379
Baseline FPG, mg/dL (mmol/L)
 Per unit increase 1.01 (1.00, 1.03) 0.055 1.01 (1.00, 1.03) 0.149
 100–<126 (5.6–<7.0) vs <100 (<5.6) 1.63 (0.99, 2.69) 0.055 0.97 (0.52, 1.82) 0.93
 ≥126 (≥7.0) vs <100 (<5.6) 1.58 (0.63, 3.97) 0.327 1.29 (0.55, 3.02) 0.561
Baseline HbA1c, % (mmol/mol)
 Per unit increase 2.79 (1.74, 4.50) <0.0005 4.30 (2.14, 8.64) <0.0005
 5.7–<6.5 (37.7–<47.5) vs <5.7 (<37.7) 3.34 (2.03, 5.52) <0.0005 2.37 (1.18, 4.77) 0.015
 6.5–<8.0 (47.5–<63.9) vs <5.7 (<37.7) 3.23 (1.38, 7.53) 0.007  8.65 (2.76, 27.05) <0.0005
 6.5–<8.0 (47.5–<63.9) vs 5.7–<6.5 (37.7–<47.5) 0.96 (0.43, 2.14) 0.929 3.64 (1.34, 9.92) 0.012
History of diabetes mellitus
 Diabetic vs NGT 4.74 (2.66, 8.47) <0.0005  4.80 (1.66, 13.91) 0.004
 Pre-diabetic vs NGT 2.94 (1.73, 5.01) <0.0005 1.21 (0.36, 4.11) 0.756
History of hypertension
 Yes vs no 2.38 (1.46, 3.88) <0.0005 1.56 (0.87, 2.80) 0.133
History of dyslipidemia
 Yes vs no 1.83 (1.08, 3.12) 0.026 3.59 (1.83, 7.05) <0.0005
Mean baseline GH, μg/L
 Per unit increase 1.01 (1.00, 1.02) 0.131 1.00 (0.99, 1.01) 0.772
Baseline IGF-I × ULN
 Per unit increase 1.00 (1.00, 1.00) 0.298 1.00 (1.00, 1.00) 0.361
 FPG, fasting plasma glucose; GH, growth hormone; HbA1c, glycated hemoglobin; IGF-I, insulin-like growth factor I;  NGT, normal glucose tolerance; ULN, 
upper limit of normal.
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Mean HbA1c and FPG over time by baseline diabetic status and pasireotide treatment in the core phases of studies C2305 and C2402. Data are presented 
as mean ± s.e. Numbers below the horizontal axes refer to numbers of patients in the diabetic/pre-diabetic/NGT groups. FPG, fasting plasma glucose; 
HbA1c, glycated hemoglobin; NGT, normal glucose tolerance.
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Median FPG and HbA1c over time by antidiabetic treatment category for patients on pasireotide who did not have antidiabetic treatment at baseline and 
started antidiabetic intervention during the core phases of studies C2305 and C2402. Data presented as median values. Numbers below the horizontal 
axes refer to numbers of patients in the metformin alone/metformin ± OAD/insulin ± OAD groups in panels A and B, and the metformin alone/metformin 
± OAD groups in panels C and D. In panels C and D, only two patients who had no antidiabetic medication at baseline in the pasireotide 60 mg group 
received insulin ± OAD during study C2402. This group is not shown because of difficulties interpreting the median for two patients. FPG, fasting plasma 
glucose; HbA1c, glycated hemoglobin; OAD, oral antidiabetic drug.
Table 3 Incidence and severity of hyperglycemia-related AEs in patients receiving pasireotide, according to diabetic status.a
Diabetic Pre-diabetic Normal glucose tolerance
C2305 C2402a C2305 C2402a C2305 C2402a
40 mg 40 mg 60 mg 40 mg 40 mg 60 mg 40 mg 40 mg 60 mg
n 53 45 37 68 11 13 57 7 12
Hyperglycemia-related  
AEs, n (%)
37 (69.8) 32 (71.1) 26 (70.3) 40 (58.8) 7 (63.6) 6 (46.2) 25 (43.9) 3 (42.9) 6 (50.0)
Grade 3–4 AEs, n (%) 10 (18.9) 7 (15.6) 9 (24.3) 4 (5.9) 0 0 2 (3.5) 0 0
aThe number of patients deemed to be diabetic, pre-diabetic or have normal glucose tolerance at baseline in this analysis of the C2402 study is different 
from the number classified as such in the primary publication of the study because the definitions of diabetic, pre-diabetic and normal glucose tolerance 
are slightly different in this analysis compared with those in the primary publication; the definitions were updated for this analysis to align them with 
guidelines set by the American Diabetes Association for the classification of diabetes.
AE, adverse event.
This work is licensed under a Creative Commons 
Attribution 4.0 International License.https://doi.org/10.1530/EC-20-0361
https://ec.bioscientifica.com © 2020 The authors
Published by Bioscientifica Ltd
Downloaded from Bioscientifica.com at 01/13/2021 12:30:50PM
via free access





the extension phase of study C2305. Mean glucose levels 
were higher at extension baseline for patients who crossed 
over to octreotide (127.1 mg/dL (7.1 mmol/L)) than for 
those who crossed over to pasireotide (104.0 mg/dL (5.8 
mmol/L)). By month 1 of the extension phase (the earliest 
time point measured), mean glucose levels in patients who 
crossed over to octreotide from pasireotide had decreased 
to 108.6 mg/dL (6.0 mmol/L) (Fig. 3). For patients who 
crossed over to octreotide, mean glucose and HbA1c levels 
at 3 months post-crossover (103.8 mg/dL (5.8 mmol/L) 
and 6.1% (43.4 mmol/mol)) were similar to those observed 
at core baseline (97.8 mg/dL (5.4 mmol/L) and 5.9% (40.7 
mmol/mol)), with subsequent stabilization to month 12 
(Fig. 3).
Discussion
Acromegaly is associated with a wide spectrum of 
morbidities (3, 4, 21, 22), with up to 75% of patients 
exhibiting disorders of glucose metabolism (5, 23, 24, 25). 
Consistent with these findings, 68 and 85% of patients 
enrolled in studies C2305 and C2402, respectively, who 
were treated with pasireotide had either diabetes or pre-
diabetes at baseline. It was expected that the proportion 
of patients categorized as diabetic or pre-diabetic at study 
entry would be higher in patients enrolled in study C2402 
because the time since diagnosis of acromegaly, and most 
likely the time of uncontrolled GH excess after diagnosis, at 
study entry was longer than in study C2305. Additionally, 
patients in study C2402 had been exposed to long-term 
treatment with first-generation somatostatin analogs, 
which may disturb glucose homeostasis (26, 27). These 
differences between the two patient populations could 
also contribute to different sensitivities in developing 
hyperglycemia while receiving pasireotide.
Pasireotide has demonstrated statistically significant 
and clinically relevant efficacy vs long-acting octreotide 
in medically naïve patients with active acromegaly, 
which is predominantly driven by greater reductions in 
IGF-I with pasireotide vs octreotide (C2305) (10), and 
vs long-acting octreotide/lanreotide Autogel in patients 
previously treated with these agents (C2402) prior to 
receiving pasireotide therapy (11). In both studies, 
suppression of GH and IGF-I levels was evident at month 
3 and sustained thereafter (10, 11). The higher binding 
affinity of pasireotide for SST5 over SST2 vs octreotide or 
lanreotide not only accounts for its superior efficacy over 
these agents, but also the increased frequency and degree 
of hyperglycemia. 
In a previous exploratory analysis of the C2402 
study, occurrence of hyperglycemia while on pasireotide 
therapy was found to be more pronounced in patients 
with pre-existing glucose abnormalities (28). This finding 
is supported in the current analysis: patients with diabetes 
at baseline had the greatest magnitude of increase in 
HbA1c following administration of pasireotide (vs patients 
with pre-diabetes or NGT). The maximal increase in mean 
FPG was observed at months 1 (C2402) and 3 (C2305) 
regardless of baseline diabetic status. In these two clinical 
trials, up to half of diabetic patients with acromegaly who 
received pasireotide were able to maintain glycemic control 
at target HbA1c values recommended by international 
guidelines for the treatment of type 2 diabetes (29).
Patients with acromegaly who achieve biochemical 
control and whose comorbidities are appropriately 
managed benefit from the most favorable clinical outcomes 
(30), to the extent that mortality approaches that of the 
general population (31). In this context, the control of 
hyperglycemia during pasireotide treatment (occurring in 
~75 and ~66% of patients in studies C2305 and C2402, 
respectively) is of paramount importance, given that type 
2 diabetes is associated with increased risk of mortality 
(32). It is important to note, however, that pasireotide 
does not cause type 2 diabetes mellitus but secondary 
diabetes, which is reversible upon discontinuation of the 
drug causing the elevations in blood glucose. As clinical 
experience with pasireotide increases, management 
of instances of hyperglycemia is expected to improve 
even further. The present work demonstrates that 
metformin monotherapy or in combination with other 
oral antidiabetic medications, such as incretin-based 
dipeptidyl peptidase 4 inhibitors, effectively controlled 
elevations in glucose levels in most pasireotide-treated 
patients. Control of hyperglycemia as defined by the ADA/
EASD (HbA1c <7% (<53.0 mmol/mol)) at last available 
assessment was achieved in ~78% of patients in study 
C2305 and ~73 (pasireotide 40 mg) and ~60% (pasireotide 
60 mg) of patients in study C2402. The UK prospective 
diabetes study demonstrated that any reduction in 
HbA1c level in patients with diabetes is associated with 
a reduced risk of complications, with each 1% reduction 
corresponding to a 37% decreased risk of microvascular 
complications and a 21% decreased risk of any endpoint 
or death related to diabetes (33). Notably, results from two 
large trials (ACCORD and ADVANCE) showed no benefit 
with regard to cardiovascular outcomes by intensively 
treating patients with diabetes to obtain HbA1c levels 
of <6.5% (<47.5 mmol/mol) (34, 35), informing the 
ADA/EASD recommendation of an HbA1c level of <7% 
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Change in (A) mean glucose levels and (B) mean 
HbA1c after crossover in study C2305. Numbers 
below the horizontal axes refer to numbers of 
patients who crossed over to long-acting 
pasireotide/crossed over to long-acting 
octreotide. HbA1c, glycated hemoglobin; LAR, 
long-acting release.
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(<53.0 mmol/mol) for the control of diabetes (36). These 
results, combined with findings from our analysis, suggest 
that, with proactive monitoring and prompt management, 
pasireotide-associated hyperglycemia is unlikely to impact 
on long-term clinical outcomes, although further studies 
are warranted.
As only two patients were treated with a GLP-1 agonist 
in these two clinical trials, no information on the use of 
these agents in patients with acromegaly can be obtained. 
However, experience with managing pasireotide-related 
hyperglycemia in patients with Cushing’s disease has led 
to the following recommendations on managing elevated 
blood glucose levels in these patients. Hyperglycemia 
should be managed by initiation of metformin and staged 
treatment intensification with a dipeptidyl peptidase 4 
inhibitor, with a switch to a GLP-1 receptor agonist and 
initiation of insulin, as required, to achieve and maintain 
glycemic control (37). Indeed, GLP-1 receptor agonists are 
often used in clinical practice to manage hyperglycemia 
during pasireotide treatment in patients with acromegaly. 
Results from this study revealed that 66–75% of 
acromegaly patients treated with pasireotide developed 
hyperglycemia; 15–30% of patients achieved biochemical 
control on pasireotide, which was similar for patients 
who did and did not experience hyperglycemia. Although 
achieving biochemical control during pasireotide therapy 
did not appear to decrease the risk of hyperglycemia, 
younger age (<40 years), normal BMI, and the absence 
of comorbidities such as diabetes, hypertension, and 
dyslipidemia at baseline were associated with less 
likelihood of developing hyperglycemia. These findings do 
not imply, however, that older patients with comorbidities 
will necessarily experience hyperglycemia when treated 
with pasireotide, only that they are at higher risk. 
Taking the aforementioned findings together 
with the low rate of discontinuations attributable 
to hyperglycemia-related AEs across both study 
populations, hyperglycemia during pasireotide treatment 
is manageable in most patients, even in those with pre-
existing glucose abnormalities, as long as glucose levels 
are closely monitored. Notably, the C2305 and C2402 
studies allowed for the inclusion of patients with a new 
diagnosis or known history of diabetes but not those with 
poorly controlled disease (HbA1c >8% despite receipt of 
antidiabetic treatment). Importantly, increases in glucose 
levels during pasireotide treatment are reversible upon 
discontinuation of pasireotide therapy, supported by the 
decrease in glucose levels in patients who switched from 
long-acting pasireotide to long-acting octreotide in the 
extension phase of study C2305. 
On a practical level, patients receiving pasireotide 
should be assessed for clinical benefit while on treatment. 
Blood glucose should be monitored in all patients, but 
with special attention given to patients with pre-existing 
impaired glucose tolerance or diabetes mellitus. If blood 
glucose levels increase, appropriate action should be 
taken, including the addition of antidiabetic medication. 
If hyperglycemia cannot be managed, discontinuation of 
pasireotide treatment can rapidly restore glucose levels to 
those seen prior to initiation of treatment.
The role of pasireotide in the acromegaly therapeutic 
continuum remains a key question for clinicians. Given 
the substantial burden of uncontrolled acromegaly and 
greater efficacy of pasireotide over first-generation SSAs 
(10, 11), pasireotide is an important treatment option for 
patients who remain uncontrolled on first-generation SSAs, 
the standard of medical care. Moreover, pasireotide may 
also be a useful treatment option in circumstances where 
alleviating tumor burden is strongly desired and surgery is 
not an option. The effect of pasireotide on reducing tumor 
volume in patients with acromegaly is well established 
(10, 38), and results of a recent subanalysis of a prospective 
open-label study (PAPE) provide additional insights 
into the antitumor effects of pasireotide. Of 47 patients 
treated with pasireotide in the study, hyperintensity of 
the tumor on T2-weighted MRI (typically indicative of 
cystic degeneration, tumor cell necrosis, or both) was 
observed in 10 patients within 9 months of treatment and 
in an additional four after the end of the study (median 
29.5 months’ treatment) (39). Further studies evaluating 
whether the antitumor effects of pasireotide are sustained 
following pasireotide discontinuation are of great interest. 
Such studies may be especially important considering 
the potential for a few pasireotide recipients to develop 
hyperglycemia necessitating treatment cessation (~4% of 
patients in studies C2305 and C2402 combined). 
In conclusion, increasing age and the presence of 
impaired glucose tolerance, dyslipidemia or hypertension 
appears to increase the likelihood of developing 
hyperglycemia during pasireotide treatment. However, 
hyperglycemia was manageable in most patients treated 
in studies C2305 and C2402, regardless of age or 
comorbidities present, with very few instances of these 
AEs necessitating discontinuation of pasireotide in the 
two studies.
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